Phaseline

Targets › FTSZ

FTSZ: drug programs, companies and trials

6 programs from 4 companies in 14 trials: 7 Phase 4, 4 Phase 1, 3 Phase 3; Other, Infectious disease, Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on FTSZ, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Abdul El-RabbanyCefazolin
Bacterial penicillin-binding protein inhibitor
FTSZPhase 4Orthognathic Surgical Site InfectionJan 2027
Uppsala UniversityPivmecillinam
Beta-lactam antibiotic that inhibits bacterial cell wall synthesis
FTSZPhase 4Febrile Urinary Tract InfectionMar 2029
Qilu PharmaceuticalMeropenem
Bacterial penicillin-binding protein inhibitor
FTSZPhase 3Hospital-acquired Bacterial Pneumonia (HABP); Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia; MDR Bacteria; Febrile Neutropenia …Dec 2026
Basilea PharmaceuticaCeftibuten
Bacterial penicillin-binding protein inhibitor
FTSZPhase 1Healthy VolunteerDec 2026
Basilea PharmaceuticaCeftibuten-ledaborbactam etzadroxil
Beta-lactam antibiotic combined with beta-lactamase inhibitor
FTSZPhase 1Healthy VolunteerDec 2026
Basilea PharmaceuticaLedaborbactam etzadroxil
Beta-lactamase inhibitor
FTSZPhase 1Healthy VolunteerDec 2026

Conditions

Sepsis (3) Healthy Volunteer (3) Hospital-acquired Bacterial Pneumonia (HABP) (1) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (1) MDR Bacteria (1) Febrile Neutropenia (1) Infection (1) Bloodstream Infection (1) Febrile Urinary Tract Infection (1) Orthognathic Surgical Site Infection (1)

Modalities

small molecule (6)

Companies

Basilea Pharmaceutica (3) Qilu Pharmaceutical (1) Uppsala University (1) Abdul El-Rabbany (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.